{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:39:10Z","timestamp":1775705950953,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.phymed.2017.09.004","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T01:15:58Z","timestamp":1506042958000},"page":"54-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients"],"prefix":"10.1016","volume":"36","author":[{"given":"Friedemann","family":"Schad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Thronicke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Merkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Matthes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan L.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2017.09.004_bib0001","unstructured":"Abnoba GmbH, 2014. Information for Healthcare Professionals."},{"key":"10.1016\/j.phymed.2017.09.004_bib0002","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12885-016-2594-5","article-title":"Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer","volume":"16","author":"Axtner","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phymed.2017.09.004_bib0003","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/BF00180280","article-title":"Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients","volume":"70","author":"Beuth","year":"1992","journal-title":"Clin. Invest."},{"key":"10.1016\/j.phymed.2017.09.004_bib0004","unstructured":"B\u00fcssing, A., Raak, C., Ostermann, T., 2012. Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): a meta-analysis. Evidence-based complementary and alternative medicine: eCAM 2012, 219402."},{"key":"10.1016\/j.phymed.2017.09.004_bib0005","first-page":"23","article-title":"Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins","volume":"19","author":"B\u00fcssing","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phymed.2017.09.004_bib0006","first-page":"1893","article-title":"Local reactions to treatments with Viscum album L. extracts and their association with T-lymphocyte subsets and quality of life","volume":"28","author":"B\u00fcssing","year":"2008","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phymed.2017.09.004_bib0007","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.it.2015.02.006","article-title":"Immune-mediated mechanisms influencing the efficacy of anticancer therapies","volume":"36","author":"Coffelt","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.phymed.2017.09.004_bib0008","first-page":"2945","article-title":"Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity","volume":"29","author":"Elluru","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phymed.2017.09.004_bib0009","unstructured":"European Commission, 2009. A guideline on summary of product characteristics (SmPC)."},{"key":"10.1016\/j.phymed.2017.09.004_bib0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000069428","article-title":"Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo","volume":"16","author":"Hajto","year":"1998","journal-title":"Natural Immun."},{"key":"10.1016\/j.phymed.2017.09.004_bib0011","doi-asserted-by":"crossref","unstructured":"Horneber, M.A., Bueschel, G., Huber, R., Linde, K., Rostock, M., 2008. Mistletoe therapy in oncology. Cochrane Database Syst. Rev., CD003297.","DOI":"10.1002\/14651858.CD003297.pub2"},{"key":"10.1016\/j.phymed.2017.09.004_bib0012","unstructured":"ICH Steering Committee, 1994. E2A: clinical safety data management: definitions and standards for expedited reporting. 2\u20133."},{"key":"10.1016\/j.phymed.2017.09.004_bib0013","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1472-6882-11-72","article-title":"Safety of higher dosages of Viscum album L. in animals and humans\u2013systematic review of immune changes and safety parameters","volume":"11","author":"Kienle","year":"2011","journal-title":"BMC Complementary Altern. Med."},{"key":"10.1016\/j.phymed.2017.09.004_bib0014","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/1534735410369673","article-title":"Review article: influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies","volume":"9","author":"Kienle","year":"2010","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.phymed.2017.09.004_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/4628287","article-title":"Intravenous mistletoe treatment in integrative cancer care: a qualitative study exploring the procedures, concepts, and observations of expert doctors","volume":"2016","author":"Kienle","year":"2016","journal-title":"Evidence-Based Complementary Altern. Med."},{"key":"10.1016\/j.phymed.2017.09.004_bib0016","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3892\/or.2012.1812","article-title":"Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer","volume":"28","author":"Ohki","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phymed.2017.09.004_bib0017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7453\/gahmj.2012.1.1.006","article-title":"Durable regression of primary cutaneous b-cell lymphoma following fever-inducing mistletoe treatment: two case reports","volume":"1","author":"Orange","year":"2012","journal-title":"Global Adv. Health Med.: Improv. Healthcare Outcomes Worldwide"},{"key":"10.1016\/j.phymed.2017.09.004_bib0018","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1534735416649916","article-title":"Coley's lessons remembered: augmenting mistletoe therapy","volume":"15","author":"Orange","year":"2016","journal-title":"Integ. Cancer Ther."},{"key":"10.1016\/j.phymed.2017.09.004_bib0019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3835(96)04401-1","article-title":"Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes","volume":"109","author":"Ribereau-Gayon","year":"1996","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2017.09.004_bib0020","first-page":"369","article-title":"Network oncology (NO) \u2013 a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine","volume":"20","author":"Schad","year":"2013","journal-title":"Forschende Komplementarmedizin"},{"key":"10.1016\/j.phymed.2017.09.004_bib0021","first-page":"785","article-title":"QuaDoSta (quality assurance, documentation and statistics) - a flexible, platform-independent, open source database for oncological documentation","volume":"130","author":"Schad","year":"2004","journal-title":"Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.phymed.2017.09.004_bib0022","first-page":"1","article-title":"Fever therapy with intravenously applied mistletoe extracts for cancer patients: a retrospective study","author":"Schl\u00e4ppi","year":"2016","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.phymed.2017.09.004_bib0028","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7812\/TPP\/15-018","article-title":"High-dose Viscum album extract treatment in the prevention of recurrent bladder cancer: a retrospective case series","volume":"19","author":"von Schoen-Angerer","year":"2015","journal-title":"Permanente J."},{"key":"10.1016\/j.phymed.2017.09.004_bib0023","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phymed.2017.09.004_bib0024","doi-asserted-by":"crossref","first-page":"23837","DOI":"10.1039\/C5RA27381A","article-title":"European Viscum album: a potent phytotherapeutic agent with multifarious phytochemicals, pharmacological properties and clinical evidence","volume":"6","author":"Singh","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.phymed.2017.09.004_bib0025","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1016\/j.ejca.2013.06.043","article-title":"Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival","volume":"49","author":"Tr\u00f6ger","year":"2013","journal-title":"Euro. J. Cancer"},{"key":"10.1016\/j.phymed.2017.09.004_bib0026","series-title":"Mistletoe: From Mythology to Evidence-Based Medicine","first-page":"11","article-title":"Chemical constituents of Viscum album L.: implications for the pharmaceutical preparation of mistletoe","author":"Urech","year":"2015"},{"key":"10.1016\/j.phymed.2017.09.004_bib0027","series-title":"Common Terminology Criteria For Adverse Events (CTCAE) Version 4.0","year":"2009"},{"key":"10.1016\/j.phymed.2017.09.004_bib0029","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.phymed.2012.11.001","article-title":"Durable response of cutaneous squamous cell carcinoma following high-dose peri-lesional injections of Viscum album extracts\u2013a case report","volume":"20","author":"Werthmann","year":"2013","journal-title":"Phytomed.: Int. J. Phytother. Phytopharmacol."},{"key":"10.1016\/j.phymed.2017.09.004_bib0030","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/14712598.2010.482207","article-title":"Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression","volume":"10","author":"Whiteside","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.phymed.2017.09.004_bib0031","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.phymed.2011.09.027","article-title":"High dose intravenous mistletoe treatment - clinical results, laboratory findings and adverse events in a series of 17 patients with 107 intravenous applications","volume":"18","author":"Wiebelitz","year":"2011","journal-title":"Phytomed.: Int. J. Phytother. Phytopharmacol."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711317301204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711317301204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T01:31:44Z","timestamp":1659490304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711317301204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":31,"alternative-id":["S0944711317301204"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2017.09.004","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2017.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}